For the year ending 2025-12-31, CME had $62,285,400K increase in cash & cash equivalents over the period. $4,193,600K in free cash flow.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Net income | 4,072,200 | 3,525,800 | 3,226,200 | 2,691,000 |
| Stock-based compensation | 94,800 | 89,500 | 82,900 | 84,300 |
| Amortization of purchased intangibles | 223,400 | 221,700 | 226,600 | 227,700 |
| Depreciation and amortization | 107,500 | 115,100 | 126,000 | 134,900 |
| Net losses on assets held for sale and impaired | - | - | - | 0 |
| Gain on sale of building | - | - | 0 | 0 |
| Gain on joint venture | - | - | 0 | 0 |
| (gain)/loss on derivative contracts | - | - | - | 0 |
| Net realized and unrealized gains on investments | 352,800 | 3,600 | 72,100 | 4,800 |
| Deferred income taxes | -6,100 | -66,400 | -75,000 | -23,200 |
| Accounts receivable | 67,100 | 39,400 | 51,500 | 51,100 |
| Other current assets | 18,100 | -664,800 | 637,800 | 76,500 |
| Other assets | -49,900 | -75,400 | -92,000 | -87,000 |
| Accounts payable | -8,100 | -10,700 | -30,800 | 72,500 |
| Income tax payable | 91,100 | -117,400 | -77,100 | -147,800 |
| Other current liabilities | 86,600 | -705,900 | 642,700 | 88,100 |
| Other liabilities | -34,600 | -55,400 | -32,700 | -67,400 |
| Other | -38,400 | 3,000 | -34,400 | -41,300 |
| Net cash provided by operating activities | 4,277,100 | 3,690,500 | 3,453,800 | 3,056,000 |
| Proceeds from maturities and sales of available-for-sale marketable securities | 7,900 | 6,000 | 5,900 | 6,300 |
| Purchases of available-for-sale marketable securities | 6,000 | 4,500 | 4,100 | 4,400 |
| Purchases of property, net | 83,500 | 94,000 | 76,400 | 89,700 |
| Investments in business ventures | 11,000 | 3,600 | 2,400 | 3,100 |
| Proceeds from sale of business ventures | 1,591,400 | 13,500 | 97,900 | 11,100 |
| Payment for acquisition of subsidiary's interests from the non-controlling interest | - | - | 0 | 0 |
| Proceeds from the sale of building property | - | - | 0 | 0 |
| Net cash proceeds from osttra joint venture transaction | - | - | 0 | 0 |
| Investment in s&p dow jones indices llc | - | 0 | 0 | 410,000 |
| Net cash used in investing activities | 1,498,800 | -82,600 | 20,900 | -489,800 |
| Repayment issuance of commercial paper, net | - | - | - | 0 |
| Proceeds from debt, net of issuance costs | 740,600 | 0 | 0 | 741,000 |
| Repayment of other borrowings, including call premiums | 750,000 | 0 | 16,400 | 756,200 |
| Proceeds from preferred stock offering | - | - | 0 | 0 |
| Cash dividends | 3,933,000 | 3,584,200 | 3,235,500 | 2,633,500 |
| Payments for (proceeds from) derivative instrument, financing activities | 266,100 | - | - | - |
| Change in performance bond and guaranty fund contributions | 60,760,600 | 8,702,900 | -45,056,700 | -22,700,300 |
| Employee taxes paid on restricted stock vesting | 33,900 | 33,000 | 21,400 | 24,800 |
| Other | -8,700 | -9,200 | -9,300 | -7,900 |
| Cash provided by (used in) financing activity, including discontinued operation | 56,509,500 | 5,076,500 | -48,339,300 | -25,381,700 |
| Cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect | 62,285,400 | 8,684,400 | -44,864,600 | -22,815,500 |
| Cash, cash equivalents, restricted cash and restricted cash equivalents, beginning balance | 101,794,100 | 93,109,700 | 137,974,300 | 160,789,800 |
| Cash, cash equivalents, restricted cash and restricted cash equivalents, ending balance | 164,079,500 | 101,794,100 | 93,109,700 | 137,974,300 |
CME GROUP INC. (CME)
CME GROUP INC. (CME)